Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 12:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 170 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors Clear all
Completed Phase 2 Interventional Results available

Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma

NCT00400569
View directory record Official record
Conditions
Liposarcoma, Leiomyosarcoma, Fibrosarcoma, Malignant Fibrous Histiocytoma
Interventions
Sunitinib Malate (SU011248)
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 28, 2012 · Synced Oct 12, 2026, 12:57 PM EDT
Completed Phase 1 Interventional

LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer

NCT00005858
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer
Interventions
LMB-9 immunotoxin
Biological
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
2
States / cities
Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Oct 12, 2026, 12:57 PM EDT
Completed Not applicable Interventional Results available

Prospective Trial of EUS-FNA Versus EUS-FNB Using a Novel Core Biopsy Needle

NCT01769248
View directory record Official record
Conditions
Pancreatic Cancer, Lymphadenopathy, Gastrointestinal Stromal Tumor
Interventions
Fine needle aspiration, Fine needle biopsy
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 90 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Los Angeles, California • San Francisco, California • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 12, 2026, 12:57 PM EDT
Recruiting Phase 2 Interventional

Imatinib TDM in GIST

NCT05493215
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors
Interventions
Imatinib
Drug
Lead sponsor
Reema A. Patel
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 12, 2026, 12:57 PM EDT
Completed Phase 4 Interventional Results available

Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study

NCT01735955
View directory record Official record
Conditions
Chronic Myelogenous Leukemia (CML), Metastatic Gastrointestinal Stromal Tumors (GIST), Acute Lymphoblastic Leukemia (ALL), Receptor Tyrosine Kinase (KIT) Mutated Melanoma
Interventions
Nilotinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
2
States / cities
Albany, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Oct 12, 2026, 12:57 PM EDT
Completed Phase 2 Interventional Results available

Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)

NCT03556384
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors, Sdh, GIST, Cancer
Interventions
Temozolomide
Drug
Lead sponsor
Adam Burgoyne, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
4
States / cities
La Jolla, California • Miami, Florida • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 12, 2026, 12:57 PM EDT
Completed Not applicable Interventional

Effect of Imatinib on Bone Metabolism in Patients With Chronic Myelogenous Leukemia or Gastrointestinal Stromal Tumors

NCT00580281
View directory record Official record
Conditions
Gastric Cancer, Leukemia, Chronic Myelogenous Leukemia
Interventions
blood test, urine test, and bone density x-ray.
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2013 · Synced Oct 12, 2026, 12:57 PM EDT
Completed Phase 1 Interventional

Ipilimumab and Imatinib Mesylate in Advanced Cancer

NCT01738139
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, C-KIT Tyrosine Kinase Protein Overexpression, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Gastrointestinal Stromal Tumor, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Melanoma, Unresectable Solid Neoplasm
Interventions
Imatinib Mesylate, Ipilimumab
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Oct 12, 2026, 12:57 PM EDT
Completed Phase 2 Interventional Results available

Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib

NCT01831726
View directory record Official record
Conditions
Tumor Pathway Activations Inhibited by Dovitinib
Interventions
Dovitinib (TKI258)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
49
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Pismo Beach, California + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 12, 2026, 12:57 PM EDT
Completed Phase 2 Interventional

Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery

NCT00025246
View directory record Official record
Conditions
Gastrointestinal Stromal Tumor
Interventions
imatinib mesylate, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Oct 12, 2026, 12:57 PM EDT
Completed Phase 3 Interventional Results available

A Study of Nilotinib Versus Imatinib in GIST Patients

NCT00785785
View directory record Official record
Conditions
Gastrointestinal Stromal Tumor (GIST)
Interventions
Nilotinib (AMN107), imatinib (STI571)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
644 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
28
States / cities
Birmingham, Alabama • Flagstaff, Arizona • Duarte, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Oct 12, 2026, 12:57 PM EDT
Completed No phase listed Observational

Gastrointestinal Stromal Tumors (GIST) Registry

NCT00507273
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors
Interventions
GIST Registry
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2012 · Synced Oct 12, 2026, 12:57 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor

NCT00069940
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Gastrointestinal Stromal Tumor, Sarcoma
Interventions
sargramostim, telomerase: 540-548 peptide vaccine
Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
2 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 28, 2010 · Synced Oct 12, 2026, 12:57 PM EDT
Completed Phase 2 Interventional

Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas

NCT00005874
View directory record Official record
Conditions
Gastrointestinal Stromal Tumor, Sarcoma, Small Intestine Cancer
Interventions
rubitecan
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Dublin, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 12, 2026, 12:57 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies

NCT05957367
View directory record Official record
Conditions
GIST
Interventions
Inlexisertib, Ripretinib
Drug
Lead sponsor
Deciphera Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
11
States / cities
Los Angeles, California • Miami, Florida • Worcester, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 12, 2026, 12:57 PM EDT
Completed Phase 1 Interventional

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

NCT00161187
View directory record Official record
Conditions
Cancer
Interventions
therapeutic allogeneic lymphocytes
Biological
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 6, 2015 · Synced Oct 12, 2026, 12:57 PM EDT
Completed Phase 2 Interventional Results available

Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor

NCT01068769
View directory record Official record
Conditions
Gastrointestinal Stromal Tumor
Interventions
regorafenib
Drug
Lead sponsor
Suzanne George, MD
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
4
States / cities
Boston, Massachusetts • Portland, Oregon • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 24, 2020 · Synced Oct 12, 2026, 12:57 PM EDT
Approved For Marketing No phase listed Expanded access

A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248

NCT00094029
View directory record Official record
Conditions
Gastrointestinal Neoplasm
Interventions
Sutent
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
32
States / cities
Duarte, California • Pasadena, California • San Francisco, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2012 · Synced Oct 12, 2026, 12:57 PM EDT
Completed Phase 1Phase 2 Interventional

Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction

NCT00004911
View directory record Official record
Conditions
Colorectal Cancer, Constipation, Impaction, and Bowel Obstruction, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Gastrointestinal Stromal Tumor, Quality of Life, Small Intestine Cancer
Interventions
bowel obstruction management, quality-of-life assessment
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Oct 12, 2026, 12:57 PM EDT
Completed Phase 1 Interventional

A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients

NCT01735968
View directory record Official record
Conditions
3rd Line GIST
Interventions
ST571 + BYL719
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 12, 2026, 12:57 PM EDT
Completed Phase 2 Interventional Results available

Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors

NCT01560260
View directory record Official record
Conditions
Carney Complex, Chondrosarcoma, Gastrointestinal Stromal Tumor, Paraganglioma
Interventions
Laboratory Biomarker Analysis, Linsitinib, Pharmacological Study
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
8
States / cities
Palo Alto, California • Iowa City, Iowa • Bethesda, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2018 · Synced Oct 12, 2026, 12:57 PM EDT
Completed Phase 1Phase 2 Interventional

A Study of LY2880070 in Participants With Advanced or Metastatic Cancer

NCT02632448
View directory record Official record
Conditions
Solid Tumors, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Colon Cancer, Rectal Cancer, Neoplasms, Endometrial Cancer, Soft Tissue Sarcoma, Triple Negative Breast Cancer, Pancreas Cancer, Pancreatic Cancer
Interventions
LY2880070, Gemcitabine
Drug
Lead sponsor
Esperas Pharma Inc.
Other
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 12, 2026, 12:57 PM EDT
Completed Not applicable Interventional Results available

Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer

NCT00253708
View directory record Official record
Conditions
Cancer
Interventions
management of therapy complications, massage therapy, pain therapy, psychosocial assessment and care, quality-of-life assessment
Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Oct 12, 2026, 12:57 PM EDT
Completed Phase 1 Interventional

Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib

NCT00441155
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors
Interventions
Nilotinib, Imatinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 13, 2013 · Synced Oct 12, 2026, 12:57 PM EDT